Enveric Biosciences, Inc. 8-K

What Happened

• On February 6, 2026, Enveric Biosciences, Inc. (ENVB) filed a prospectus supplement to register an additional $1,346,000 of shares of its common stock under its At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. The ATM Agreement is dated April 9, 2025. The company previously sold $1,853,878.34 of common stock through the Sales Agent under this ATM. A legal opinion from Greenberg Traurig, LLP regarding the shares is included as an exhibit to the 8-K.

Key Details

• Prospectus supplement filed: February 6, 2026.
• Additional registration amount: $1,346,000 of common stock.
• Sales agent: H.C. Wainwright & Co., LLC; ATM Agreement dated April 9, 2025.
• Prior sales under ATM: $1,853,878.34 of common stock (aggregate).

Why It Matters

• This filing increases the amount of common stock Enveric can sell into the open market through its existing ATM facility, giving the company capacity to raise additional capital as needed. For existing shareholders, additional shares registered under the ATM can lead to dilution if and when the company actually sells shares. The 8-K does not announce any immediate sales—only that more shares are now registered for potential issuance under the ATM.